Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT06788509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
December 30, 2024
Completion date
December 29, 2028
Enrollment
120 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic, b-cell, leukemia, myeloid, acute, lymphoma, non-hodgkin, myelodysplastic syndromes, neoplasms, prostatic neoplasms, castration-resistant, solid tumor, adult